checkAd

     162  0 Kommentare First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca - Seite 4

    This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

    Lesen Sie auch

    For additional information, please contact:

    Investors

    Innate Pharma
    Tel.: +33 (0)4 30 30 30 30
    investors@innate-pharma.com





    		 Media

    Innate Pharma
    Tracy Rossin (Global/US)
    Tel.: +1 240 801 0076
    Tracy.Rossin@innate-pharma.com

    ATCG Press
    Marie Puvieux (France)
    Tel.: +33 (0)9 81 87 46 72
    innate-pharma@atcg-partners.com

    Seite 4 von 4



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca - Seite 4 Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy and PD-(L)1 inhibitor MARSEILLE, France, Oct. 23, …